medigraphic.com
ISSN 0138-7103 (Print)

2012, Number 3

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2012; 9 (3)

Premature ejaculation. Development in its treatment

Correa JM

Language: Spanish
References: 33
Page:
PDF size: 230.32 Kb.


ABSTRACT

The premature ejaculation (PE) is nowadays probably the sexual dysfunction more frequent in the masculine sex and it is defined by social and cultural factors and the establishment of “compensatory” methods. Premature ejaculation causes several affections for the person who suffers from it in the social, psychological or family environment. Its frequency is higher than the dysfunction, but with better levels of acceptance. Among the associated factors that lead to its occurrence are the biological causes, the possible endocrinopathies, genetic tendency and psychological causes. Among the therapeutic options are shown the psychotherapeutic treatments from the tendencies of conduction, topic agents based in their majority on spray and creams with anesthetics components and other systemic treatments mainly based on anesthetics and ant depressive, as well as , the combination of methods and several pharmacs getting then greater levels of effectiveness. Finally, it is proposed the antidepressive Dapoxetine that shows good level of response. In the these paper was done a review of the theme deeping in aspect related with the masculine sexual answer and its treatment. With this objective the more updated works published in Pubmed and Medline were reviewed. Conclusions: The premature ejaculation is a world problem and although the several variables of treatment is still a masculine resistance to accept it as a disorder and therefore to its treatment. The SRSI and specially Dapoxetine constitute a variable of an effective treatment.


REFERENCES

  1. Montorsi F, Prevalence of premature ejaculation A global and regional perspective:. J Sex Med. 2005;2(Suppl 2):96–102

  2. Moreira ED Jr, Brock G, Glasser DB, et al. Help-seeking behaviour for sexual problems: the Global Study of Sexual Attitudes and Behaviors Int J Clin Pract. 2005;59(1):6–16

  3. Rösing D, Klebingat K, Berberich HJ, Bosinski HA, Loewit K. Male Sexual Dysfunction. Diagnosis and Treatment From a Sexological and Interdisciplinary Perspective. Dtsch Arztebl Int. 2009 December; 106(50): 821–828

  4. Nolas Acarín T. Sexo y sexualidad. En: El cerebro del rey. La Habana: Editorial científico-Técnica; 2008.p 68-147

  5. Puentes Rodríguez Y, Alfonso Bécquer C. Diagnóstico y tratamiento de la eyaculación precoz. En: Salud sexual y práctica sexológica. La Habana: Editorial CENESEX; 2008. P. 53-81

  6. Štulhofer A, Bajić Ž. Prevalence of Erectile and Ejaculatory Difficulties among Men in Croatia. Croat Med J. 2006 February; 47(1): 114–124.

  7. Wolters JP, Hellstrom WJ. Current concepts in ejaculatory dysfunction. Rev Urol. 2006;8(suppl 4):18–25

  8. Foreman MM, Hall JL, Love RL. The role of the 5-HT2 receptor in the regulation of sexual performance of male rats. Life Sci. 1989;45:1263–70

  9. Ahlenius S, Larsson K, Svensson L, et al. Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav. 1981;15:785–92

  10. Mohee A, Eardley I. Medical therapy for premature ejaculation. Ther Adv Urol. 2011 October; 3(5): 211–222.

  11. Wylie KR, Ralph D. Premature ejaculation: the current literatura. Curr Opin Urol. 2005;15:393–398

  12. Waldinger MD. Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med. 2008;29:50–69

  13. Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy Behav Res Therapy. 1986; 24: 665–675.

  14. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000;55:257–261

  15. Choi HK, Xin ZC, Choi YD, Lee WH, Mah SY, Kim DK. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a doublé-blind, randomized, placebo controlled clinical study. Int J Impot Res. 1999; 11(5):261–264.

  16. Busato W, Galindo CC. Topical anesthetic use for treating premature ejaculation: a doublé blind, randomized, placebo-controlled study. B J U Int. 2004; 93: 1018–1021.

  17. Atikeler M., Gecit I., Senol F. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andologia 2002; 34: 356–359

  18. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5min before intercourse in men with premature ejaculation: results of a phase III, multicentre, doublé-blind, placebo controlled study. B J U Int. 2009; 103: 940–949.

  19. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009 Apr; 103(7):940-9.

  20. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCl has promise in an on-demand use to treat premature ejaculation. J Sex Med. 2008;5(1):188–193

  21. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a Doublé-blind, placebo controlled, fixed dose, randomized study. J Clin Psychopharmacol. 2006;26(1):27–31

  22. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a doublé-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998;18(4):274–281

  23. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14(6):502–505

  24. McMahon C, Park NC, Zhao Y, Rothman M, Rivas D. Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of Dapoxetine Oral presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine; October 6–10, 2007

  25. Buvat J, Giuliano F, Tesfaye F, Rothman M, Rivas D. Efficacy and safety of dapoxetine for premature ejaculation (PE): results from a placebo-controlled, double-blind, randomized, parallel-group study in 22 countries. Urology. 2007;70(3):15

  26. McMahon CG, Stuckey BG, Andersen M, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2(3):368–375

  27. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008;80(2):162–165

  28. Chen J, Mabjeesh NJ, Matzkin H, et al. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003;61:197–200

  29. Mattos RM, Lucon AM. AUA Annual Meeting.. Tadalafil and slow-release fluoxetine in premature ejaculation:a prospective study. San Antonio, TX; 2005

  30. Sommer F, Klotz T, Mathers MJ. AUA Annual Meeting. Treatment of premature ejaculation:a comperative vardenafil and SSRI crossover study. San Antonio, TX: 2005.

  31. Kim JJ, Kwak TI, Jeon BG, Cheon J, Moon DG. Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. Int J Impot Res. 2004;16:547–551

  32. Yin TL, Yang J, Zhang B. Folic acid supplementation as adjunctive treatment premature ejaculation. Med Hypotheses. 2011 Mar;76(3):414-6

  33. Linton KD, Wylie KR. Recent advances in the treatment of premature ejaculation. Drug Des Devel Ther. 2010; 4: 1–6.




2020     |     www.medigraphic.com